Thermo Fisher Scientific (TMO) Common Equity (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Common Equity for 18 consecutive years, with $52.7 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 4.38% year-over-year to $52.7 billion; the trailing twelve-month figure through Jun 2026 stood at $52.7 billion (up 4.38% YoY), and the FY2025 full-year result was $53.4 billion, up 7.8% from the prior year.
• Common Equity rose to $52.7 billion in Q2 2026 per TMO's latest filing, from $51.9 billion in the prior quarter.
• Across five years, Common Equity topped out at $53.4 billion in Q4 2025 and bottomed at $41.0 billion in Q2 2022.
• Historically, Common Equity has averaged $47.2 billion across 5 years, with a median of $47.1 billion in 2023.
• The sharpest annual moves came in 2022 and 2023: Common Equity advanced 16.97% in 2022, then advanced 3.15% in 2023.
• Over 5 years, Common Equity stood at $44.0 billion in 2022, then climbed by 6.11% to $46.7 billion in 2023, then advanced by 6.05% to $49.6 billion in 2024, then grew by 7.8% to $53.4 billion in 2025, then fell by 1.36% to $52.7 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $52.7 billion, $51.9 billion, and $53.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.